{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:57:15Z","timestamp":1790056635429,"version":"4.0.1"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2019-0010_s_020_w2aab3b7b2b1b6b1aab1c16b1Aa\">\n                    <jats:title id=\"d5917655e5742_w2aab3b7b2b1b6b1aab1c16b1aAa\">Background<\/jats:title>\n                    <jats:p>Malignant peritoneal mesothelioma (MPM) is a rare tumoral disease characterized by the diffuse involvement of the peritoneal serosa. The standard frontline treatment of MPM is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) unless the peritoneal disease is considered unresectable. For unresectable patients the standard frontline treatment is a combination of cisplatin and pemetrexed but the prognosis remains ominous with only 13 months of overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0010_s_021_w2aab3b7b2b1b6b1aab1c16b2Aa\">\n                    <jats:title id=\"d5917655e5751_w2aab3b7b2b1b6b1aab1c16b2aAa\">Methods<\/jats:title>\n                    <jats:p>The proposed study is a multicenter randomized non-comparative study evaluating the association of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy vs. systemic chemotherapy alone as first-line treatment of MPM. Patients will be randomized with a 2:1 ratio using a minimization technique. Sixty-six patients have to be enrolled. Stratification will be performed according to histology (epithelioid vs. sarcomatoid and biphasic), presence of extraperitoneal disease and center. Primary objective is OS and secondary objectives include progression-free survival (PFS), safety, compliance, feasibility, conversion to resectability, histological response to treatment and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0010_s_022_w2aab3b7b2b1b6b1aab1c16b3Aa\">\n                    <jats:title id=\"d5917655e5760_w2aab3b7b2b1b6b1aab1c16b3aAa\">Conclusions<\/jats:title>\n                    <jats:p>We expect to show that intensification of the first line treatment with PIPAC for initially unresectable MPM patients increases OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0010_s_023_w2aab3b7b2b1b6b1aab1c16b4Aa\">\n                    <jats:title id=\"d5917655e5769_w2aab3b7b2b1b6b1aab1c16b4aAa\">Trial registration<\/jats:title>\n                    <jats:p>Prospective study. Clinicaltrials.gov: NCT03574493 EudraCT: 2019\u2013001515-23.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2019-0010","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T05:02:47Z","timestamp":1561611767000},"source":"Crossref","is-referenced-by-count":28,"title":["MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma"],"prefix":"10.1515","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6965-3697","authenticated-orcid":false,"given":"Olivia","family":"Sgarbura","sequence":"first","affiliation":[{"name":"Surgical oncology Department , Montpellier Cancer Institute (ICM), University of Montpellier , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gourgou","sequence":"additional","affiliation":[{"name":"Biometrics Unit , Montpellier Cancer Institute (ICM), University of Montpellier , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Tosi","sequence":"additional","affiliation":[{"name":"Early phase clinical trial unit , Montpellier Cancer Institute (ICM), University of Montpellier , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoual","family":"Bakrin","sequence":"additional","affiliation":[{"name":"Surgery Department , Lyon Sud University Hospital, Claude Bernard University , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabila","family":"Bouazza","sequence":"additional","affiliation":[{"name":"Clinical Research Department , Montpellier Cancer Institute (ICM), Univ. Montpellier , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Delaine","sequence":"additional","affiliation":[{"name":"Clinical Research Department , Montpellier Cancer Institute (ICM), Univ. Montpellier , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"De Forges","sequence":"additional","affiliation":[{"name":"Clinical Research Department , Montpellier Cancer Institute (ICM), Univ. Montpellier , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[{"name":"INSERM U1275, CAP Paris-Tech, Carcinomatosis Peritoneum Paris Technology, Lariboisi\u00e8re Hospital , AP-HP, 2 rue Ambroise Par\u00e9 \u2013 75010 Paris \u2013 Universit\u00e9 de Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Qu\u00e9net","sequence":"additional","affiliation":[{"name":"Surgical oncology Department , Montpellier Cancer Institute (ICM), University of Montpellier , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,6,27]]},"reference":[{"key":"2025120909240995867_j_pp-2019-0010_ref_001_w2aab3b7b2b1b6b1ab1b4b1Aa","doi-asserted-by":"crossref","unstructured":"Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 2017;5:236.10.21037\/atm.2017.03.9628706904","DOI":"10.21037\/atm.2017.03.96"},{"key":"2025120909240995867_j_pp-2019-0010_ref_002_w2aab3b7b2b1b6b1ab1b4b2Aa","doi-asserted-by":"crossref","unstructured":"Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985\u201390.10.1093\/annonc\/mdl34517030547","DOI":"10.1093\/annonc\/mdl345"},{"key":"2025120909240995867_j_pp-2019-0010_ref_003_w2aab3b7b2b1b6b1ab1b4b3Aa","doi-asserted-by":"crossref","unstructured":"Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39:576\u201388.10.1080\/1040844090304492819650718","DOI":"10.1080\/10408440903044928"},{"key":"2025120909240995867_j_pp-2019-0010_ref_004_w2aab3b7b2b1b6b1ab1b4b4Aa","doi-asserted-by":"crossref","unstructured":"Boffetta P, Tubiana M, Hill C, Boniol M, Aurengo A, Masse R, et al. The causes of cancer in France. Ann Oncol. 2009;20:550\u20135.10.1093\/annonc\/mdn59718765462","DOI":"10.1093\/annonc\/mdn597"},{"key":"2025120909240995867_j_pp-2019-0010_ref_005_w2aab3b7b2b1b6b1ab1b4b5Aa","doi-asserted-by":"crossref","unstructured":"Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier AM, et al. Survival of cancer patients in France: a population-based study from the association of the French cancer registries (FRANCIM). Eur J Cancer. 2007;43:149\u201360.10.1016\/j.ejca.2006.07.021","DOI":"10.1016\/j.ejca.2006.07.021"},{"key":"2025120909240995867_j_pp-2019-0010_ref_006_w2aab3b7b2b1b6b1ab1b4b6Aa","doi-asserted-by":"crossref","unstructured":"Alexander HR Jr, Li CY, Kennedy TJ. Current management and future opportunities for peritoneal metastases: peritoneal mesothelioma. Ann Surg Oncol. 2018;25:2159\u201364.2942366410.1245\/s10434-018-6337-5","DOI":"10.1245\/s10434-018-6337-5"},{"key":"2025120909240995867_j_pp-2019-0010_ref_007_w2aab3b7b2b1b6b1ab1b4b7Aa","doi-asserted-by":"crossref","unstructured":"Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19:1416\u201324.10.1245\/s10434-012-2237-222302266","DOI":"10.1245\/s10434-012-2237-2"},{"key":"2025120909240995867_j_pp-2019-0010_ref_008_w2aab3b7b2b1b6b1ab1b4b8Aa","doi-asserted-by":"crossref","unstructured":"Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237\u201342.1991786210.1200\/JCO.2009.23.9640","DOI":"10.1200\/JCO.2009.23.9640"},{"key":"2025120909240995867_j_pp-2019-0010_ref_009_w2aab3b7b2b1b6b1ab1b4b9Aa","doi-asserted-by":"crossref","unstructured":"Malgras B, Gayat E, Aoun O, Lo DR, Eveno C, Pautrat K, et al. Impact of combination chemotherapy in peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy (HIPEC): the RENAPE study. Ann Surg Oncol. 2018;25:3271\u20139.2997836610.1245\/s10434-018-6631-2","DOI":"10.1245\/s10434-018-6631-2"},{"key":"2025120909240995867_j_pp-2019-0010_ref_010_w2aab3b7b2b1b6b1ab1b4c10Aa","doi-asserted-by":"crossref","unstructured":"Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. May 2015;22:1686\u201393.10.1245\/s10434-014-3978-x","DOI":"10.1245\/s10434-014-3978-x"},{"key":"2025120909240995867_j_pp-2019-0010_ref_011_w2aab3b7b2b1b6b1ab1b4c11Aa","doi-asserted-by":"crossref","unstructured":"Janne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, et al. Open-label study of Pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7:40\u20136.1609824310.3816\/CLC.2005.n.020","DOI":"10.3816\/CLC.2005.n.020"},{"key":"2025120909240995867_j_pp-2019-0010_ref_012_w2aab3b7b2b1b6b1ab1b4c12Aa","doi-asserted-by":"crossref","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of Pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.1286093810.1200\/JCO.2003.11.136","DOI":"10.1200\/JCO.2003.11.136"},{"key":"2025120909240995867_j_pp-2019-0010_ref_013_w2aab3b7b2b1b6b1ab1b4c13Aa","doi-asserted-by":"crossref","unstructured":"Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, et al. Malignant peritoneal mesothelioma-results from the international expanded access program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211\u201318.1904205310.1016\/j.lungcan.2008.08.013","DOI":"10.1016\/j.lungcan.2008.08.013"},{"key":"2025120909240995867_j_pp-2019-0010_ref_014_w2aab3b7b2b1b6b1ab1b4c14Aa","doi-asserted-by":"crossref","unstructured":"Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L. Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. Expert Opin Investig Drugs. 2017;26:933\u201344.2867929110.1080\/13543784.2017.1351545","DOI":"10.1080\/13543784.2017.1351545"},{"key":"2025120909240995867_j_pp-2019-0010_ref_015_w2aab3b7b2b1b6b1ab1b4c15Aa","doi-asserted-by":"crossref","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405\u201314.2671923010.1016\/S0140-6736(15)01238-6","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"2025120909240995867_j_pp-2019-0010_ref_016_w2aab3b7b2b1b6b1ab1b4c16Aa","doi-asserted-by":"crossref","unstructured":"Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 2018;19:e161\u2013e172.10.1016\/S1470-2045(18)30100-1","DOI":"10.1016\/S1470-2045(18)30100-1"},{"key":"2025120909240995867_j_pp-2019-0010_ref_017_w2aab3b7b2b1b6b1ab1b4c17Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43:1228\u201335.10.1016\/j.ejso.2017.01.00928189456","DOI":"10.1016\/j.ejso.2017.01.009"},{"key":"2025120909240995867_j_pp-2019-0010_ref_018_w2aab3b7b2b1b6b1ab1b4c18Aa","doi-asserted-by":"crossref","unstructured":"Le RF, Gelli M, Hollebecque A, Honore C, Boige V, Dartigues P, et al. Conversion to complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma after bidirectional chemotherapy. Ann Surg Oncol. 2017;24:3640\u20136.2884938910.1245\/s10434-017-6033-x","DOI":"10.1245\/s10434-017-6033-x"},{"key":"2025120909240995867_j_pp-2019-0010_ref_019_w2aab3b7b2b1b6b1ab1b4c19Aa","doi-asserted-by":"crossref","unstructured":"Alyami M, Gagniere J, Sgarbura O, Cabelguenne D, Villeneuve L, Pezet D, et al. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43:2178\u201383.10.1016\/j.ejso.2017.09.01028964609","DOI":"10.1016\/j.ejso.2017.09.010"},{"key":"2025120909240995867_j_pp-2019-0010_ref_020_w2aab3b7b2b1b6b1ab1b4c20Aa","doi-asserted-by":"crossref","unstructured":"Girshally R, Demtroder C, Albayrak N, Zieren J, Tempfer C, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2016;14:253.10.1186\/s12957-016-1008-027678344","DOI":"10.1186\/s12957-016-1008-0"},{"key":"2025120909240995867_j_pp-2019-0010_ref_021_w2aab3b7b2b1b6b1ab1b4c21Aa","doi-asserted-by":"crossref","unstructured":"Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, Hubner M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg. 2017;104:669\u201378.2840722710.1002\/bjs.10521","DOI":"10.1002\/bjs.10521"},{"key":"2025120909240995867_j_pp-2019-0010_ref_022_w2aab3b7b2b1b6b1ab1b4c22Aa","doi-asserted-by":"crossref","unstructured":"Giger-Pabst U, Demtroder C, Falkenstein TA, Ouaissi M, Gotze TO, Rezniczek GA, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer. 2018;18:442.2966952410.1186\/s12885-018-4363-0","DOI":"10.1186\/s12885-018-4363-0"},{"key":"2025120909240995867_j_pp-2019-0010_ref_023_w2aab3b7b2b1b6b1ab1b4c23Aa","doi-asserted-by":"crossref","unstructured":"Kepenekian V, Elias D, Passot G, Mery E, Goere D, Delroeux D, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. Eur J Cancer. 2016;65:69\u201379.10.1016\/j.ejca.2016.06.00227472649","DOI":"10.1016\/j.ejca.2016.06.002"},{"key":"2025120909240995867_j_pp-2019-0010_ref_024_w2aab3b7b2b1b6b1ab1b4c24Aa","doi-asserted-by":"crossref","unstructured":"Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA. A phase I, single-arm, open-label, ose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol. 2018;150:23\u201330.10.1016\/j.ygyno.2018.05.001","DOI":"10.1016\/j.ygyno.2018.05.001"},{"key":"2025120909240995867_j_pp-2019-0010_ref_025_w2aab3b7b2b1b6b1ab1b4c25Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum. 2016;1:99\u2013107.30911613","DOI":"10.1515\/pp-2016-0011"},{"key":"2025120909240995867_j_pp-2019-0010_ref_026_w2aab3b7b2b1b6b1ab1b4c26Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Sempoux C, Carr NJ, Bibeau F, Neureiter D, Jager T, et al. Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis. Histopathology. 2019;74:1014\u201324.3068794410.1111\/his.13829","DOI":"10.1111\/his.13829"},{"key":"2025120909240995867_j_pp-2019-0010_ref_027_w2aab3b7b2b1b6b1ab1b4c27Aa","unstructured":"www.clinicaltrials.gov. Accessed 1 May 2019."},{"key":"2025120909240995867_j_pp-2019-0010_ref_028_w2aab3b7b2b1b6b1ab1b4c28Aa","doi-asserted-by":"crossref","unstructured":"Villeneuve L, Passot G, Glehen O, Isaac S, Bibeau F, Rousset P, et al. The RENAPE observational registry: rationale and framework of the rare peritoneal tumors french patient registry. Orphanet J Rare Dis. 2017;12:37.2821268410.1186\/s13023-017-0571-y","DOI":"10.1186\/s13023-017-0571-y"},{"key":"2025120909240995867_j_pp-2019-0010_ref_029_w2aab3b7b2b1b6b1ab1b4c29Aa","doi-asserted-by":"crossref","unstructured":"Alyami M, Kim BJ, Villeneuve L, Vaudoyer D, Kepenekian V, Bakrin N, et al. Ninety-day post-operative morbidity and mortality using the National Cancer Institute\u2019s common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia. 2018;34:532\u20137.10.1080\/02656736.2017.136784628838265","DOI":"10.1080\/02656736.2017.1367846"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/4\/2\/article-20190010.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0010\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0010\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:01:33Z","timestamp":1765278093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0010\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6,28]]},"published-print":{"date-parts":[[2019,6,26]]}},"alternative-id":["10.1515\/pp-2019-0010"],"URL":"https:\/\/doi.org\/10.1515\/pp-2019-0010","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,1]]},"article-number":"20190010"}}